Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afamelanotide pharmacokinetics study in adolescent and adult patients with erythropoietic protoporphyria
NL-OMON60129Phase 2Completed
- Sponsor
- Clinuvel Pharmaceuticals
- Start
- May 2024
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of Afamelanotide in erythropoietic protoporphyria (EPP), sponsored by Clinuvel Pharmaceuticals. Started May 2024; status: completed.
02
Drugs
Afamelanotide
03
Conditions
erythropoietic protoporphyria (EPP)
Beyond the preview
Go deeper on NL-OMON60129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60129.